AndreaBozzo/ceres-open-data-index huggingface dataset:
Cisatracurium besylate

Cisatracurium Besylate is a generic prescription drug used as a neuromuscular blocker to relax muscles during surgery or mechanical ventilation. It's administered intravenously as an injection in strengths of 2 mg/mL or 10 mg/mL. Manufactured by Zydus Pharmaceuticals USA Inc., it's approved under ANDA212171. This information was generated using AI and is provided for informational and research purposes only.
Compound 525170: Nonaethylene glycol, diacetate

Chemical compound data from PubChem database. IUPAC Name: 2-[2-[2-[2-[2-[2-[2-[2-(2-acetyloxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl acetate. Molecular Formula: C22H42O12. Molecular Weight: 498.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Collaborative interactions between neutrophil elastase and metalloproteinases in extracellular matrix degradation in three-dimensional collagen gels

Background
          Extended culture of monocytes and fibroblasts in three-dimensional collagen gels leads to degradation of the gels (see linked study in this issue, "Fibroblasts and monocytes contract and degrade three-dimensional collagen gels in extended co-culture"). The current study, therefore, was designed to evaluate production of matrix-degrading metalloproteinases by these cells in co-culture and to determine if neutrophil elastase could collaborate in the activation of these enzymes. Since co-cultures produce prostaglandin E2 (PGE2), the role of PGE2 in this process was also evaluated.
        
        
          Methods
          Blood monocytes from healthy donors and human fetal lung fibroblasts were cast into type I collagen gels and maintained in floating cultures for three weeks. Matrix metalloproteinases (MMPs) were assessed by gelatin zymography (MMPs 2 and 9) and immunoblotting (MMPs 1 and 3). The role of PGE2 was explored by direct quantification, and by the addition of exogenous indomethacin and/or PGE2.
        
        
          Results
          Gelatin zymography and immunoblots revealed that MMPs 1, 2, 3 and 9 were induced by co-cultures of fibroblasts and monocytes. Neutrophil elastase added to the medium resulted in marked conversion of latent MMPs to lower molecular weight forms consistent with active MMPs, and was associated with augmentation of both contraction and degradation  (P < 0.01). PGE2 appeared to decrease both MMP production and activation.
        
        
          Conclusion
          The current study demonstrates that interactions between monocytes and fibroblasts can mediate tissue remodeling.
2012 NSSATS - Data on Substance Abuse Treatment Facilities

This report presents results from the 2012 National Survey of Substance Abuse Treatment Services (N-SSATS), an annual census of facilities providing substance abuse treatment. Conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA), N-SSATS is designed to collect data on the location, characteristics, and use of alcohol and drug abuse treatment facilities and services throughout the 50 states, the District of Columbia, and other U.S. jurisdictions.
New York State Lead Service Line Inventory

This dataset includes information about New York State lead service lines, including service line materials, material identification methods, and service line installation dates.

On December 16, 2021, the federal Lead and Copper Rule Revisions (LCRR) went into effect, which requires every federally defined community and non-transient, non-community water system to develop a service line inventory and to make this information publicly available.

If you have any questions about your service line, please contact your water system. The public water system contact information can be found on your water bill or online at:
<a href=https://health.ny.gov/environmental/water/drinking/pws_contacts/map_pws_contacts>https://health.ny.gov/environmental/water/drinking/pws_contacts/map_pws_contacts</a>
Compound 529366: Lys, N-isoBOC TBDMS

Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] 2,6-bis(2-methylpropoxycarbonylamino)hexanoate. Molecular Formula: C22H44N2O6Si. Molecular Weight: 460.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Behavioral Health Barometer: Rhode Island, 2014

This is a behavioral health report for the state of Rhode Island. It uses the  National Survey on Drug Use and Health (NSDUH) and the National Survey of Substance Abuse Treatment Services (NSSATS) to address the topics of youth substance use , youth mental health and treatment, adult mental health and treatment, substance use, substance use treatment, and medicare enrollees for the years 2009 to 2013.
Patent AT-E40135-T1: [Translated] (1,2,4-TRIAZOLE-1-YL)-METHYL-CARBINOLS.

1,2,4-Triazol-1-yl-methyl-carbinols of the formula   <IMAGE>   in which Ar is optionally substituted aryl, and Het is optionally substituted heteroaryl with at least 2 different hetero-atoms, or addition products thereof with plant-tolerated acids or metal salts, which possess fungicidal activity.
NNDSS - Table II. Invasive Pneumococcal to Legionellosis

NNDSS - Table II. Invasive Pneumococcal to Legionellosis - 2014.In this Table, all conditions with a 5-year average annual national total of more than or equals 1,000 cases but less than or equals 10,000 cases will be displayed (��� 1,000 and ��_ 10,000). The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data.  Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable.    -: No reported cases.    N: Not reportable.    NN: Not Nationally Notifiable    Cum: Cumulative year-to-date counts.    Med: Median.    Max: Maximum. * Case counts for reporting years 2013 and 2014 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. ��� Includes drug resistant and susceptible cases of Invasive Pneumococcal Disease. This condition was previously named Streptococcus pneumoniae invasive disease and cases were reported to CDC using different event codes to specify whether the cases were drug resistant or in a defined age group, such as < 5 years. Since 2010, case notifications for this condition were consolidated under one event code for Invasive pneumococcal disease.More information on NNDSS is available at http://wwwn.cdc.gov/nndss/.
National Directory of Drug and Alcohol Abuse Treatment Facilities 2005

The National Directory of Drug and Alcohol Abuse Treatment Programs 2005 lists federal, state, local, and private facilities that provide substance abuse treatment services. The directory includes treatment facilities that are licensed, certified, or otherwise approved for inclusion in the directory by their state substance abuse agencies and that responded to the 2004 National Survey of Substance Abuse Treatment Services (N-SSATS). The information about each facility that appears in this directory was provided by that facility in response to the 2004 N-SSATS. The Substance Abuse and Mental Health Services Administration (SAMHSA) conducts the N-SSATS annually.
Patent AT-E401258-T1: [Translated] SELF-VENTING LID FOR A HEATABLE FOOD PACK

A self-venting cover for a heatable food package comprises a sheet of film having a slit formed therein to permit the passage of steam therethrough. A label is secured to the film for controlling the flow of steam through the opening. The label includes a sheet of material having a first region secured to the film in an area remote from the slit and having a second elongated region covering the slit. The elongated region is only partially secured to the film and forms a vent passage between the unsecured portion of the elongated region and the film itself, which vent passage extends from the slit towards the periphery of the label to permit controlled venting of steam from the opening. The elongated region of the label is relatively narrow and the first region is relatively wide and is located spaced from the opening.
LDL-cholesterol lowering effect of a generic product of simvastatin compared to simvastatin (Zocor™) in Thai hypercholesterolemic subjects – a randomized crossover study, the first report from Thailand

Background
          It is commonly agreed that people with a high blood LDL-cholesterol will have a higher risk of coronary artery disease (CAD) than people with low blood LDL-cholesterol. Due to the increasingly high costs of medication in Thailand, the government has set up several measures to combat the problem. One of such strategies is to promote the utilization of locally manufactured drug products, especially those contained in the National Drug List. Simvastatin, an HMG-CoA reductase inhibitor, is listed as an essential drug for the treatment of hypercholesterolemia. Here, we reported the study on the LDL-cholesterol-lowering effect of a generic simvastatin product in comparison with the Zocor©, in 43 healthy thai  volunteers.
        
        
          Method
          The generic product tested  was Eucor©, locally manufactured by Greater Pharma Ltd., Part, Thailand, and the reference product was Zocor© (Merck Sharp & Dohme, USA). The two products were administered as 10-mg single oral doses in a two-period crossover design. After drug administration, serial blood samples were collected every 4 weeks for 16 weeks. The major parameter monitored in this study was blood LDL-cholesterol.
        
        
          Result
          After taking the drugs for the first 8 weeks, no statistically significant difference was dedected in blood LDL-cholesterol between the first (Zocor©-treated) and the second (Eucor©-treated) groups. After crossover and taking drugs for further 8 weeks, a similar result was obtained, i.e., no significant difference in blood LDL-cholesterol between the first (Eucor©-treated) and the second (Zocor©-treated) groups was observed. Upon completion of the 16-week study, there was also no statisticaly significant difference in the changes of all tested blood parameters between the two products (randomized block ANOVA, N = 37). Only minor side effects, mainly dizziness and nausea, were observed in both products.
        
        
          Conclusion
          Our study demonstrated no significant differences in the therapeutic effect and safety between the generic and original simvastatin products.
Long-term experience with implanted intrathecal drug administration systems for failed back syndrome and chronic mechanical low back pain

Background
          Continuous intrathecal drug delivery has been shown in open studies to improve pain and quality of life in those with intractable back pain who have had spinal surgery. There is limited data on long term effects and and even less for patients with mechanical back pain without prior spinal surgery.
        
        
          Methods
          We have investigated spinal drug administration systems for patients with failed back syndrome and chronic mechanical low back pain by patient questionnaire study of the efficacy of this therapy and a case notes review.
        
        
          Results
          36 patients (97% of 37 approached) completed questionnaires, 24 with failed back syndrome and 12 with chronic mechanical low back pain. Recalled pre-treatment levels with current post-treatment levels of pain and a range of quality of life measures (recorded on 11-point numerical rating scales) were compared. Pain improved significantly in both groups (Wilcoxan signed ranks test, p < 0.005). The majority of quality of life measures improved significantly in the failed back syndrome group (Wilcoxan signed ranks test, p < 0.005) although work interruption and the effect of pain on sex life did not change. There was a trend towards improvement in the majority of quality of life measures in the mechanical back pain group but this did not reach statistical significance due to the smaller numbers in this cohort (p > 0.005, Wilcoxan signed ranks test with Bonferroni correction).
          Diamorphine was used in all 37 patients, bupivacaine in 32, clonidine in 27 and baclofen in 3. The mean dose of diamorphine increased for the first 2 years but did not change 2–6 years post implant, averaging 4.5 mg/day. Revision surgery was required in 24% of cases, but reduced to 12% in the later years of our experience.
        
        
          Conclusions
          We conclude that spinal drug administration systems appear to be of benefit in alleviating pain in the failed back syndrome and chronic mechanical low back pain but need to be examined prospectively.
National Youth Victimization Prevention Survey, 1992-1994

There were two primary goals of the National Youth Victimization Prevention Study.  One was to derive estimates of various forms of victimization among youths.  The other was to obtain children’s assessments of the victimization prevention programs which many schools have begun offering over the past decade.  Data were collected by telephone survey from 2000 children between the ages of 10 and 16 and their caretakers.  Children were interviewed at two time points, the initial survey time and a 15 month follow-up.  In addition to collecting basic demographic information, the survey asked children to recall details of victimizations personally experienced, respond to a test of knowledge about sexual victimization, recall the content of prevention programs to which they were exposed, render judgments regarding the usefulness of these programs, report on behavioral, social and psychological troubles (including offense behavior and substance abuse), and express opinions on a range of topics including the level of crime in their schools and in their neighborhoods, and reaction to the survey itself.

Investigators: Finkelhor, David
PLACES: Local Data for Better Health, Place Data 2020 release

This dataset contains model-based place (incorporated and census designated places) level estimates for the PLACES project 2020 release. The PLACES project is the expansion of the original 500 Cities project and covers the entire United States—50 states and the District of Columbia (DC)—at county, place, census tract, and ZIP Code tabulation Areas (ZCTA) levels. It represents a first-of-its kind effort to release information uniformly on this large scale for local areas at 4 geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. The project was funded by the Robert Wood Johnson Foundation (RWJF) in conjunction with the CDC Foundation. The dataset includes estimates for 27 measures: 5 chronic disease-related unhealthy behaviors, 13 health outcomes, and 9 on use of preventive services. These estimates can be used to identify emerging health problems and to inform development and implementation of effective, targeted public health prevention activities. Because the small area model cannot detect effects due to local interventions, users are cautioned against using these estimates for program or policy evaluations. Data sources used to generate these model-based estimates  include Behavioral Risk Factor Surveillance System (BRFSS) 2018 or 2017 data, Census Bureau 2010 population data, and American Community Survey (ACS) 2014-2018 or 2013-2017 estimates. The 2020 release uses 2018 BRFSS data for 23 measures and 2017 BRFSS data for 4 measures (high blood pressure, taking high blood pressure medication, high cholesterol, and cholesterol screening). Four measures are based on the 2017 BRFSS because the relevant questions are only asked every other year in the BRFSS. More information about the methodology can be found at www.cdc.gov/places.
2022-2023 NSDUH: Geographic Comparisons for State Prevalence Estimates

Compare state and regional estimates for measures of substance use and mental health using p-values. The tables are a companion to the state-level estimatetablesfrom the 2022-2023 National Surveys on Drug Use and Health (NSDUH). This resource includes both the p-value tables and a guide for their use in determining whether differences between two geographic areas are statistically significant.The tables are available in an Excel spreadsheet or a zip file containing CSV text files. Each tab or text file contains all the geographies for a particular measure and a particular age group.
IHS Facility Locator

<p>This map can be used to find an Indian Health Service, Tribal or Urban Indian Health Program facility. This map can be used to:&#13;<br />
Zoom in to a general location to see if there is a facility in that region.&#13;<br />
Enter your current location in the form to see the facilities available.&#13;<br />
Find a specific facility by selecting the "Facility Information" tab and typing in the name of the facility that you are trying to find.&#13;</p>
Information Memorandum (IM-90-18)

This Information Memorandum (IM) establishes FY 1990 allotments for title IV-B and procedures for applying for: (1) A State's 1990; (2) reallotted IV-B funds and (3) funds to be transferred from title IV-E foster care. Share of funds available under title IV-B in FY.

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E399613-T1: [Translated] SHORT CIRCUIT WELDING DEVICE

Chemical patent from PubChem database. Patent Number: AT-E399613-T1. Title: Chemical Synthesis Method. Filing Date: 1995-04-01. Inventors: Smith, John A., Johnson, Mary B.. Abstract: A novel method for chemical synthesis is provided, utilizing specific catalysts and reaction conditions to achieve selective transformations with high... IPC Classifications: C07H, A61K, A61P. This patent covers 36 claims related to 4 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.
Compound 526320: 2,3,6,8-Tetrabromo-dibenzofuran

Chemical compound data from PubChem database. IUPAC Name: 2,3,6,8-tetrabromodibenzofuran. Molecular Formula: C12H4Br4O. Molecular Weight: 483.77. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400828-T1: [Translated] OPTICAL ELEMENT WITH MICROPRISM STRUCTURE FOR DIRECTING LIGHT BEAMS

An optical element (10, 10', 10'') for deflecting light beams (18, 19), which enter and re-emerge from the latter, in such a way that their angle of emergence (gamma) is limited, in particular for use as a luminaire-cover, having a plate-like core (11, 11', 11'') of transparent material which on one side is occupied by microprisms (12, 13) that taper-starting from their root (15)-forming furrows (22), wherein all of the top surfaces (14) of the microprisms form the light-entry face and the other side (21) of the core forms the light-emergence face, and wherein the top surfaces (14) of the microprisms are formed convexly or concavely in a continuous or non-continuous manner, and also a method for producing the optical element (10, 10', 10'').
2013 CMHS Uniform Reporting System (URS) Table for Nebraska

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Tables for Nebraska for 2013. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program.  State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
CMS Program Statistics - Medicare Deaths

The CMS Program Statistics - Medicare Deaths summary tables provide data on Medicare deaths. 

For additional information on enrollment, providers, and Medicare use and payment, visit the CMS Program Statistics page.

 

Below is the list of tables:


	MDCR ENROLL AB 33.  Medicare Deaths:  Total (Original Medicare and Medicare Advantage and Other Health Plan) Beneficiaries, by Month of Death, Yearly Trend
	MDCR ENROLL AB 34.  Medicare Deaths:  Total, Original Medicare, and Medicare Advantage and Other Health Plan Beneficiaries, by Demographic Characteristics
	MDCR ENROLL AB 35.  Medicare Deaths:  Total (Original Medicare and Medicare Advantage and Other Health Plan) Beneficiaries, by Area of Residence
	MDCR ENROLL AB 36.  Medicare Deaths:  Original Medicare Beneficiaries, by Month of Death, Yearly Trend
	MDCR ENROLL AB 37.  Medicare Deaths:  Original Medicare Beneficiaries, by Area of Residence
	MDCR ENROLL AB 38.  Medicare Deaths:  Medicare Advantage and Other Health Plan Beneficiaries, by Month of Death, Yearly Trend
	MDCR ENROLL AB 39.  Medicare Deaths:  Medicare Advantage and Other Health Plan Beneficiaries, by Area of Residence
Compound 525233: 1-[10-[3-(Dimethylamino)propyl]phenothiazin-2-yl]ethanol

Chemical compound data from PubChem database. IUPAC Name: 1-[10-[3-(dimethylamino)propyl]phenothiazin-2-yl]ethanol. Molecular Formula: C19H24N2OS. Molecular Weight: 328.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Electronic Prescribing Adoption and Use by State

Electronic prescribing (eRx) is a key component of the meaningful use of health IT to improve health care quality and lower costs. This dataset includes national and state eRx and health information exchange activity by community pharmacies and office-based health care providers active through the Surescripts Network. Surescripts is a health information network, and ONC procured electronic prescribing activity data conducted within its network from December 2008 through April 2014. The Surescripts network is used by the majority of all U.S. community pharmacies to rout prescriptions, excluding closed systems such as Kaiser Permanente. These include chain, franchise, and independently owned pharmacies. Data for annual percentages of new and renewal prescriptions routed through the Surescripts network exclude controlled substances. You may view more information about Surescripts, contact the company, and access more network data through the company's official site.
Compound 528223: 3-Phenyl-2-quinoxalinecarbaldehyde oxime

Chemical compound data from PubChem database. IUPAC Name: 1-[2-(2-chloroethylsulfanyl)ethoxy]-2-[2-(2-chloroethylsulfanyl)ethylsulfanyl]ethane. Molecular Formula: C10H20Cl2OS3. Molecular Weight: 323.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.